Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Shares Outstanding (Weighted Average) (2016 - 2026)

Insight Molecular Diagnostics' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $30.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 133.16% to $30.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $30.5 million, a 133.16% increase, with the full-year FY2025 number at $30.5 million, up 133.16% from a year prior.
  • Shares Outstanding (Weighted Average) hit $30.5 million in Q4 2025 for Insight Molecular Diagnostics, down from $32.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for IMDX hit a ceiling of $92.2 million in Q1 2022 and a floor of $5135.0 in Q2 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $23.7 million across 5 years, with a median of $10.6 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 99.99% in 2022 and later skyrocketed 136803.6% in 2023.
  • Tracing IMDX's Shares Outstanding (Weighted Average) over 5 years: stood at $88920.0 in 2021, then soared by 6130.32% to $5.5 million in 2022, then soared by 38.1% to $7.7 million in 2023, then skyrocketed by 70.84% to $13.1 million in 2024, then skyrocketed by 133.16% to $30.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for IMDX at $30.5 million in Q4 2025, $32.0 million in Q3 2025, and $32.0 million in Q2 2025.